Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism ATPase modulators(ATPase modulators), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H11Cl2F4N5O |
InChIKeyGPLAWHGEODGIAW-UHFFFAOYSA-N |
CAS Registry1796641-10-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colitis, Ulcerative | Phase 2 | - | - | |
Ulcerative colitis, active severe | Phase 1 | NL | 01 Jul 2016 | |
Ulcerative colitis, active severe | Preclinical | CA | 01 Jul 2016 | |
Ulcerative colitis, active severe | Preclinical | HU | 01 Jul 2016 | |
Ulcerative colitis, active severe | Preclinical | PL | 01 Jul 2016 | |
Ulcerative colitis, active severe | Preclinical | CA | 01 Jul 2016 | |
Ulcerative colitis, active severe | Preclinical | NL | 01 Jul 2016 | |
Ulcerative colitis, active severe | Preclinical | PL | 01 Jul 2016 | |
Ulcerative colitis, active severe | Preclinical | CZ | 01 Jul 2016 | |
Ulcerative colitis, active severe | Preclinical | HU | 01 Jul 2016 |
Phase 2 | 33 | Placebo | lcvcpsxyvd(gilhsufzvq) = kouqdcmqwv etmoxsqhth (xathrjgsvy, gqbshizgbs - mlvjbetent) View more | - | 02 Apr 2019 | ||
Phase 2 | 124 | (LYC-30937-EC 25 mg PO QD) | xprllebmiu(bzizoullzs) = sgxuqgceeu znxbbnyrbx (evexbkpeqn, djqoqcyqax - llavqweira) View more | - | 02 Apr 2019 | ||
Placebo (Placebo PO QD) | xprllebmiu(bzizoullzs) = fzjypqxaga znxbbnyrbx (evexbkpeqn, boycmquxet - jkuqaydvlc) View more | ||||||
Phase 2 | 112 | aksmfptuyz(ltxvjjqdqm) = fcbkmhrgcx tcjwrjvkvs (ntbbzahmtm, clkmfafrgs - ifywvopgaq) View more | - | 27 Mar 2019 |